Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts’ consensus statement

Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts’ consensus statement

Pasireotide is a somatostatin analogue for the treatment of acromegaly, a chronic condition caused by excess growth hormone. Despite the therapeutic benefits of pasireotide as a second-line treatment for inadequately controlled acromegaly, a major concern is its hyperglycemic side-effect. Here, we p...

Full description

Bibliographic Details
Main Authors: Sylvère Störmann, Sebastian M. Meyhöfer, Jan B. Groener, Johanna Faust, Katharina Schilbach, Jochen Seufert, Bruno Vergès
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Endocrinology
Subjects:
acromegaly
pasireotide
hyperglycemia
diabetes mellitus
monitoring strategy
patient management
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2024.1348990/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2024.1348990/full

Similar Items